HomeAI · summaries
Storia in 2 fonti
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
Bain Capital, the Canada Pension Plan Investment Board, and Bristol Myers are doubling down on Beeline Medicines with a $126.3 million extension to the original $300 million raise.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Beeline ups its Series A round for immune drug work
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
- ·
endpoints.news
Beeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
Bain Capital, the Canada Pension Plan Investment Board, and Bristol Myers are doubling down on Beeline Medicines with a $126.3 million extension to the original $300 million raise.